Cloning and Germline Intervention: U.S. Perspectives
By Marcy Darnovsky
| 10. 13. 2003
Perspectives on Reproductive Technologies and Biomedicine
Presentation at The Within and Beyond Human Nature conference, Berlin, Germany
Unlike selective abortion and PGD, the reproductive genetic
procedures on which I'm going to focus today are not being used
in doctors' offices and fertility clinics. No human child has
been produced by means of germline engineering or reproductive
cloning. But the discussion of these possibilities is well underway
in the United States, and that discussion is itself already
shaping our political values and social futures.
I'm going to try in the next few minutes to give you a quick
overview of how germline engineering (or inheritable genetic
modification) and reproductive cloning are being discussed in
the U.S.
First a very brief description of the mainstream advocacy
in the U.S. of these techniques of inheritable genetic modification-that
is, for the production of "enhanced children," or
what the U.S. media often call "designer babies."
Second, some comments on the challenges of convincing U.S.
progressives and feminists that the adoption of these practices
would pose grave threats to their own commitments to social
justice and equality-and that opposing these procedures...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...